Cited by CrossRef (29)
- Yaeni Kim, Sung-Soo Park, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Chang-Ki Min. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study. Transplantation and Cellular Therapy 2023;29:55.e1
- Philippe Moreau, Niels W. C. J. van de Donk, Michel Delforge, Hermann Einsele, Valerio De Stefano, Aurore Perrot, Britta Besemer, Charlotte Pawlyn, Lionel Karlin, Salomon Manier, Xavier Leleu, Katja Weisel, Francesca Ghilotti, Joris Diels, Ahmed Elsada, Raul Morano, Vadim Strulev, Lixia Pei, Rachel Kobos, Jennifer Smit, Mary Slavcev, Maria-Victoria Mateos. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma. Adv Ther 2023;40:2412
- Tao Xu, James Roose, Mellissa Williamson, Ahmed Sawas, Wan-Jen Hong, Huan Jin, Kathleen Maignan, Alberto Rocci, Kasra Yousefi, Shaji Kumar, Stefka Tyanova, Tao Huang. RWD-derived response in multiple myeloma. PLoS ONE 2023;18:e0285125
- Bei Zhang, Bingyang Bian, Yanjiao Zhang, Li Zhang, Rongkui Zhang, Jiping Wang. The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently. Front. Oncol. 2022;12
- Fatih M. Uckun. Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma. Front. Oncol. 2021;11
- Denisa Nováková, Jakub Radocha. Treatment of relapsed and refractory multiple myeloma. Onkologie 2021;15:77
- Vinod Kumar Jaina, Abhisheik Eedara, Sasi Priya SVS, Surender Singh Jadav, Sabarinadh Chilaka, Ramakrishna Sistla, Sai Balaji Andugulapati. Anti-cancer activity of Biochanin A against multiple myeloma by targeting the CD38 and cancer stem-like cells. Process Biochemistry 2022;123:11
- Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Cirino Botta, Antonella Bruzzese, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Antonino Neri, Nicola Di Renzo, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Massimo Gentile. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. European J of Haematology 2022;108:178
- Myeonggu Seo, Ji-Hwan Park, Sung-Dong Kim, Kyung Un Choi, Kyu-Sup Cho. A Case of Extramedullary Plasmacytoma in Both Maxillary Sinuses. J Rhinol 2023;30:173
- Ji Hyun Lee, Yong Park, Ka-Won Kang, Je-Jung Lee, Ho Sup Lee, Hyeon-Seok Eom, Young Rok Do, Jin Seok Kim, Sung-Soo Yoon, Dong-Yeop Shin, Youngil Koh, Ki-Hyun Kim, Won Sik Lee, Jae-Cheol Jo, Yoo Jin Lee, Ji Yun Lee, Dae Sik Kim, Hyeok Shim, Myung Hee Chang, Sung-Hyun Kim, Chang-Ki Min. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Ann Hematol 2021;100:2051
- Zhao-Yun Liu, Nan-Hao Meng, Pan-Pan Cao, Feng-Ping Peng, Jing-Yi Luo, Hao Wang, Feng-Juan Jiang, Jin Lu, Rong Fu. Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load. Exp Hematol Oncol 2023;12
- Sung-Soo Park, Daehun Kwag, Jung Yeon Lee, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Seo Yeon Youn, Chang-Ki Min. Prognostic value of low muscle mass at the 12th thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study. dir 2023;29:596
- Sung-Hoon Jung. Recent advances in the treatment of multiple myeloma. J Korean Med Assoc 2023;66:245
- Fatih M. Uckun. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma. Cancers 2021;13:2018
- Jung Yeon Lee, Sung-Soo Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Chang-Ki Min. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study. J Cancer Res Clin Oncol 2023;149:11907
- Mussa Yussuf Khamis, Hui-Pan Wu, Qin Ma, Yi-Han Li, Li-Ying Ma, Xin-Hui Zhang, Hong-Min Liu. Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents. Bioorganic Chemistry 2021;109:104754
- Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Cheolwon Suh. Single-Center Real-World Experience of Multiple Myeloma in the 21st Century. Korean J Med 2022;97:125
- Bruno Almeida Costa, Tarek H. Mouhieddine, Joshua Richter. What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. Targ Oncol 2022;17:383
- Laura Gengenbach, Giulia Graziani, Heike Reinhardt, Amelie Rösner, Magdalena Braun, Mandy-Deborah Möller, Christine Greil, Ralph Wäsch, Monika Engelhardt. Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. Cancers 2021;13:4320
- Sandy Wong, Habib Hamidi, Luciano J. Costa, Selma Bekri, Natalia Neparidze, Ravi Vij, Tina G. Nielsen, Aparna Raval, Rajan Sareen, Elisabeth Wassner-Fritsch, Hearn J. Cho. Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM. Front. Immunol. 2023;14
- Ji Hyun Lee, Sung-Hyun Kim, Hye Ryeon Kim, Chang-Ki Min, Je-Jung Lee, Ho-Jin Shin, Jae-Cheol Jo, Ji Yun Lee, Joon Ho Moon, Kihyun Kim. Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma. Int J Hematol 2023;117:225
- Xiaoyan Qu, Gang An, Weiwei Sui, Tingyu Wang, Xian Zhang, Junfang Yang, Yan Zhang, Lu Zhang, Dan Zhu, Jiaqi Huang, Shigui Zhu, Xin Yao, Jing Li, Chengxiao Zheng, Kevin Zhu, Yutian Wei, Xiaoteng Lv, Liping Lan, Yihong Yao, Daobin Zhou, Peihua Lu, Lugui Qiu, Jianyong Li. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. J Immunother Cancer 2022;10:e005145
- Joshua Richter, Peggy L. Lin, Viviana Garcia‐Horton, Patricia Guyot, Erin Singh, Zheng‐Yi Zhou, Mark Sievert, Riley Taiji. Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma. Cancer Medicine 2023;12:8005
- Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Enrico Iaccino, Selena Mimmi, Paola Curci, Barbara Gamberi, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Antonino Neri, Massimo Gentile. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials. Front. Oncol. 2022;12
- Nor Hayati Ismail, Ali Mussa, Mutaz Jamal Al-Khreisat, Shafini Mohamed Yusoff, Azlan Husin, Muhammad Farid Johan, Md Asiful Islam. The Global Prevalence of Vitamin D Deficiency and Insufficiency in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis. Nutrients 2023;15:3227
- Julie Côté, Rami Kotb, Debra J. Bergstrom, Richard LeBlanc, Hira S. Mian, Ibraheem Othman, Martha L. Louzada. First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. Clinical Lymphoma Myeloma and Leukemia 2023;23:340
- Patrick Hlavacek, Alex Schepart, Alison R Silverstein, Allison A Petrilla, William Johnson, Amy Schroeder. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma. Future Oncology 2023;19:775
- Boris Bozic, Jens Rutner, Chang Zheng, Reinhard Ruckser, Flonza Selimi, Krysztina Racz, Martin Köcher, Georg Tatzreiter, Christian Sebesta. Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond. Cancers 2021;13:5036
- Eunhee Park, Hui-jin Mun, Eunju Seo, Seojin Hwang, Jae Hee Lee, Sukgil Song, Hyeran Sung, Hoi-Yul Kim, Mi-Jin Kwon. CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo. Biomedicines 2024;12:248